Welcome to our dedicated page for Cbdmd news (Ticker: YCBD), a resource for investors and traders seeking the latest updates and insights on Cbdmd stock.
cbdMD, Inc. reports developments in hemp-derived cannabinoid consumer products, including the cbdMD, Paw CBD, Bluebird Botanicals and Herbal Oasis brands.
Company news focuses on CBD product categories, THC-infused social seltzer distribution, clinical and regulatory science initiatives, acquisitions, financial results, liquidity, balance-sheet actions and exchange-listing compliance.
cbdMD, Inc. (NYSE American: YCBD) will host a conference call on February 10, 2022, at 4:15 p.m. ET to discuss its first quarter financial results for the period ending December 31, 2021. Interested parties can join domestically by calling 888-506-0062 and internationally at 973-528-0011, using access code 623328. A replay will be available until March 12, 2022, with domestic and international dial-in options provided. The conference will be accessible via a webcast that remains available until February 10, 2023.
cbdMD announced its fourth quarter and fiscal year results for the period ending September 30, 2021. Despite a challenging market with only 2.5% expected growth in the US CBD sector, cbdMD's net sales increased by 6% year-over-year to $44.5 million. Gross profit margin improved to a record 67%. However, the company reported a loss from operations of $19.6 million and a net loss of approximately $25.9 million. The fourth quarter saw a 16% decline in net sales to $9.8 million. cbdMD aims to outpace industry growth and achieve positive adjusted EBITDA, withdrawing previous sales guidance.
cbdMD, Inc. (NYSE American: YCBD, YCBDPA) will host a conference call on December 17, 2021, at 4:15 p.m. ET to discuss its September 30, 2021 fourth quarter and fiscal year-end financial results and business progress. The call follows a technical delay. Interested participants can join via domestic and international numbers provided. A teleconference replay will be available until January 15, 2022 and a webcast replay will be accessible until December 17, 2022.
cbdMD, Inc. (NYSE American: YCBD) has initiated a preclinical human study in collaboration with the University of South Carolina. The study aims to evaluate the effects of cbdMD’s proprietary cannabinoid blend on sleep, mood, and pain in healthy individuals, while also assessing key safety markers. The outcomes are intended to bolster the efficacy and safety profiles of cbdMD products for regulatory submissions. The company anticipates that findings from this study will facilitate future drug research and applications within its therapeutics division.
cbdMD, Inc. announced a conference call on December 16, 2021, at 4:15 p.m. Eastern Time to discuss its financial results for the fourth quarter and fiscal year ending September 30, 2021. This session will cover key business developments, and there are options for both domestic and international callers to join. The company is recognized for its extensive line of THC-free CBD products and is committed to transparency in its financial performance and future outlook.
cbdMD, Inc. (NYSE American: YCBD, YCBDpA) has appointed Dave Johnson as Senior Vice President of Business Development. With over 30 years in the consumer goods sector, including 20 years at PepsiCo (NASDAQ: PEP), Johnson will spearhead cbdMD's initiatives in expanding retail distribution across the U.S. He believes the CBD industry will experience significant growth in the next two years, positioning cbdMD to capitalize on this trend through its brands, including cbdMD and Paw CBD, and the new cbdMD Botanicals line.
cbdMD, Inc. (YCBD, YCBDPA) announced a multi-year exclusive agreement with Amify, an Amazon.com, Inc. (AMZN) partner, to launch CBD products on Amazon once the category is approved. This partnership includes cbdMD's leading products, such as gummies, tinctures, and skin care from cbdMD Botanicals. The agreement follows the growing interest in CBD since the Farm Bill's passage in 2018, positioning cbdMD to optimize its strategy for Amazon's platform. The company's Chairman emphasized readiness for market entry, enhancing cbdMD's distribution channels.
cbdMD, Inc. (NYSE: YCBD) has extended its advertising partnership with Spotify (NYSE: SPOT) and the Joe Rogan Experience (JRE) through 2022. The collaboration, which began in 2019, allows the company to tap into JRE's extensive audience, enhancing brand visibility in the CBD market. Co-CEO Martin Sumichrast emphasized the significance of this partnership, highlighting Rogan's credibility as a customer and advocate for the CBD community. cbdMD offers over 130 THC-free CBD products, contributing to its status as a leading brand in the industry.
cbdMD, Inc. (NYSE American: YCBD) will participate in the Jefferies Virtual West Coast Consumer Conference on November 16, 2021, with a fireside chat scheduled to begin at 9:50 AM ET. Investors can listen live via this link. cbdMD is a leading CBD brand, offering over 130 THC-free products including tinctures, gummies, and topicals, as well as a range of pet and beauty products. The company focuses on providing high-grade, U.S.-produced CBD solutions to consumers.
cbdMD, Inc. (NYSE American: YCBD) has appointed Matt Coapman as Chief Marketing Officer, bringing over 15 years of digital marketing and eCommerce experience. Previously, he was a Partner at Dingoz Consulting and the VP of Marketing for blu eCigs, where he significantly enhanced brand recognition. Coapman aims to drive sustainable growth, improve customer engagement, and enhance brand messaging within the CBD industry. cbdMD offers over 130 THC-free CBD products, including various SKUs for humans and pets, positioning itself as a leader in the market.